Ask Warren

Samsung Pharmaceutical

001360 · KOSPI · ₩001360 · 삼성제약

₩1,203▼ ₩27 (2.20%)End-of-day · Oct 30, 2026 · End-of-day prices.
Trade
Alert me
SellBuy
AnnualQuarterly

Income statement

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Revenue₩9.9B₩9B₩12B₩12B₩11B₩11B₩10B₩11B
Cost of sales₩6.9B₩3.8B₩8.5B₩8B₩8B₩7.6B₩5.6B₩6.8B
Gross profit₩3B₩5.2B₩3.3B₩4B₩2.9B₩3.7B₩4.9B₩4.3B
Operating income−₩5.1B−₩1.9B−₩5.4B−₩3.9B−₩4.3B−₩4.5B−₩2.9B−₩3.6B
Net income−₩57B₩8.8B−₩59B−₩30B₩64B₩37B−₩17B₩18B
Net income to shareholders−₩57B₩8.8B−₩59B−₩30B₩64B₩37B−₩17B₩18B

Balance sheet

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Total assets₩121B₩175B₩167B₩224B₩226B₩164B₩128B₩142B
Current assets₩31B₩36B₩39B₩62B₩37B₩42B₩47B₩56B
Cash and equivalents₩4.6B₩8B₩11B₩16B₩5.1B₩4B₩7.4B₩20B
Total liabilities₩49B₩46B₩46B₩44B₩19B₩21B₩23B₩22B
Current liabilities₩40B₩37B₩42B₩40B₩15B₩17B₩19B₩18B
Borrowings₩14B₩18B₩17B₩17B₩4B₩4B₩4B₩4B
Total equity₩72B₩130B₩121B₩180B₩207B₩143B₩106B₩120B
Shareholders' equity₩72B₩130B₩121B₩180B₩207B₩143B₩106B₩120B

Cash flow

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Cash from operations−₩608M−₩3B−₩2.9B−₩2.3B−₩804M−₩4B−₩4.7B−₩2.3B
Capital spending₩909M₩14M₩0₩30M₩10M₩14M₩51M₩250M
Free cash flow−₩1.5B−₩3B−₩2.9B−₩2.3B−₩814M−₩4B−₩4.8B−₩2.6B

Consolidated where available. Amounts in won.

Also known as: Samsung Pharmaceutical / 삼성제약 / 001360 / KRX:001360

Source: KRX statistical information